🇺🇸 FDA
Patent

US 12286405

Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase

granted A61PA61P25/00

Quick answer

US patent 12286405 (Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P25/00